Vaxart (VXRT) 10-K 24 Feb 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 23, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0000072444
Entity Registrant Name	Vaxart, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-35285
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	59-1212264
Entity Address, Address Line One	170 Harbor Way, Suite 300
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	550-3500
Title of 12(b) Security	Common stock, $0.0001 par value
Trading Symbol	VXRT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 913,148,825
Entity Common Stock, Shares Outstanding		125,810,393
Auditor Name	WithumSmith+Brown, PC
Auditor Location	San Francisco, California
Auditor Firm ID	100
ICFR Auditor Attestation Flag	true
OUM & Co LLP [Member]
Document Information [Line Items]
Auditor Name	OUM & Co. LLP
Auditor Location	San Francisco, California
Auditor Firm ID	252

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 143,745	$ 126,870
Short-term investments	22,742	0
Accounts receivable	71	334
Prepaid expenses and other current assets	2,609	1,327
Total current assets	169,167	128,531
Long-term investments	16,210	0
Property and equipment, net	6,601	1,480
Right-of-use assets, net	13,168	6,838
Intangible assets, net	10,624	15,361
Goodwill	4,508	0
Other long-term assets	890	372
Total assets	221,168	152,582
Current liabilities:
Accounts payable	3,872	2,133
Current portion of operating lease liability	1,011	2,052
Current portion of liability related to sale of future royalties	836	2,779
Other accrued current liabilities	5,064	4,799
Total current liabilities	10,783	11,763
Operating lease liability, net of current portion	11,997	5,156
Liability related to sale of future royalties, net of current portion	10,686	12,150
Other long-term liabilities	171	109
Total liabilities	33,637	29,178
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred Stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of December 31, 2021 or 2020	0	0
Common Stock: $0.0001 par value; 150,000,000 shares authorized; 125,594,393 and 110,271,093 shares issued and outstanding as of December 31, 2021 and 2020, respectively	13	11
Additional paid-in capital	406,943	272,274
Accumulated deficit	(219,351)	(148,881)
Accumulated other comprehensive loss	(74)	0
Total stockholders’ equity	187,531	123,404
Total liabilities and stockholders’ equity	$ 221,168	$ 152,582

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	125,594,393	110,271,093
Common stock, shares outstanding (in shares)	125,594,393	110,271,093

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	$ 892	$ 4,046	$ 9,862
Revenue	892	4,046	9,862
Operating expenses:
Research and development	48,749	19,863	14,540
General and administrative	21,890	15,202	6,187
Impairment of intangible assets	3,005	0	0
Restructuring charges (reversals)	0	(849)	4,920
Total operating expenses	73,644	34,216	25,647
Operating loss	(72,752)	(30,170)	(15,785)
Other income (expense):
Interest income	81	75	149
Interest expense	0	0	(315)
Non-cash interest expense related to sale of future royalties	(1,480)	(1,874)	(2,073)
Gain on sale of equipment	0	0	1
Gain on remeasurement of future royalty liability	3,789	0	0
Loss on debt extinguishment	0	0	(100)
Foreign exchange loss, net	(1)	(13)	(32)
Loss before income taxes	(70,363)	(31,982)	(18,155)
Provision for income taxes	107	238	490
Net loss	$ (70,470)	$ (32,220)	$ (18,645)
Net loss per share – basic and diluted (in dollars per share)	$ (0.58)	$ (0.36)	$ (0.86)
Shares used to compute net loss per share – basic and diluted (in shares)	121,453,723	88,295,762	21,569,523
Comprehensive loss:
Net loss	$ (70,470)	$ (32,220)	$ (18,645)
Unrealized loss on available-for-sale investments, net of tax	(74)	0	0
Comprehensive loss	(70,544)	(32,220)	(18,645)
Customer Service Contracts [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	13	198	406
Revenue	13	198	406
Government Contract [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	0	0	(20)
Revenue	0	0	(20)
Royalty [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	0	2,962	4,446
Revenue	0	2,962	4,446
Non Cash Royalty Revenue [Member]
Revenue:
Revenue from Contract with Customer, Including Assessed Tax	879	886	5,030
Revenue	$ 879	$ 886	$ 5,030

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]The March 2020 Offering [Member]Underwriters' Designees [Member]	Common Stock [Member]The March 2020 Offering [Member]	Common Stock [Member]The September 2019 Offering [Member]Underwriters' Designees [Member]	Common Stock [Member]The September 2019 Offering [Member]	Common Stock [Member]The July 2020 Offering [Member]	Common Stock [Member]The April 2019 Offering [Member]Underwriters' Designees [Member]	Common Stock [Member]The April 2019 Offering [Member]	Common Stock [Member]The December 2020 Offering [Member]	Common Stock [Member]The October 2020 Offering [Member]Underwriters' Designees [Member]	Common Stock [Member]Placement Agents' Designees [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]The March 2020 Offering [Member]Underwriters' Designees [Member]	Additional Paid-in Capital [Member]The March 2020 Offering [Member]	Additional Paid-in Capital [Member]The September 2019 Offering [Member]Underwriters' Designees [Member]	Additional Paid-in Capital [Member]The September 2019 Offering [Member]	Additional Paid-in Capital [Member]The July 2020 Offering [Member]	Additional Paid-in Capital [Member]The April 2019 Offering [Member]Underwriters' Designees [Member]	Additional Paid-in Capital [Member]The April 2019 Offering [Member]	Additional Paid-in Capital [Member]The December 2020 Offering [Member]	Additional Paid-in Capital [Member]The October 2020 Offering [Member]Underwriters' Designees [Member]	Additional Paid-in Capital [Member]Placement Agents' Designees [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]The March 2020 Offering [Member]Underwriters' Designees [Member]	Retained Earnings [Member]The March 2020 Offering [Member]	Retained Earnings [Member]The September 2019 Offering [Member]Underwriters' Designees [Member]	Retained Earnings [Member]The September 2019 Offering [Member]	Retained Earnings [Member]The July 2020 Offering [Member]	Retained Earnings [Member]The April 2019 Offering [Member]Underwriters' Designees [Member]	Retained Earnings [Member]The April 2019 Offering [Member]	Retained Earnings [Member]The December 2020 Offering [Member]	Retained Earnings [Member]The October 2020 Offering [Member]Underwriters' Designees [Member]	Retained Earnings [Member]Placement Agents' Designees [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]The March 2020 Offering [Member]Underwriters' Designees [Member]	AOCI Attributable to Parent [Member]The March 2020 Offering [Member]	AOCI Attributable to Parent [Member]The July 2020 Offering [Member]	AOCI Attributable to Parent [Member]The December 2020 Offering [Member]	AOCI Attributable to Parent [Member]The October 2020 Offering [Member]Underwriters' Designees [Member]	AOCI Attributable to Parent [Member]	The March 2020 Offering [Member]Underwriters' Designees [Member]	The March 2020 Offering [Member]	The September 2019 Offering [Member]Underwriters' Designees [Member]	The September 2019 Offering [Member]	The July 2020 Offering [Member]	The April 2019 Offering [Member]Underwriters' Designees [Member]	The April 2019 Offering [Member]	The December 2020 Offering [Member]	The October 2020 Offering [Member]Underwriters' Designees [Member]	The October 2020 Offering [Member]	Placement Agents' Designees [Member]	Total
Balances (in shares) at Dec. 31, 2018											7,141,189
Balances at Dec. 31, 2018											$ 1											$ 109,226											$ (98,016)																		$ 11,211
Issuance of common stock, net of offering costs (in shares)											1,200,000
Issuance of common stock, net of offering costs											$ 0											2,440											0																		2,440
Issuance of common stock warrants to placement agents’ designees			$ 0			$ 0				$ 0				$ 333			$ 497				$ 100				$ 0			$ 0				$ 0										$ 333			$ 497					$ 100
Issuance of common stock, pre-funded warrants and common stock warrants, net of offering costs (in shares)				925,455			26,124,828
Issuance of common stock, pre-funded warrants and common stock warrants, net of offering costs				$ 0			$ 3								$ 7,741			$ 7,239								$ 0			$ 0														$ 7,741			$ 7,242
Issuance of common stock upon exercise of pre-funded warrants (in shares)											12,265,455
Issuance of common stock upon exercise of pre-funded warrants											$ 1											1,225											0																		1,226
Issuance of common stock upon exercise of common stock warrants (in shares)											598,067
Issuance of common stock upon exercise of common stock warrants											$ 0											180											0																		180
Stock-based compensation											0											627											0																		627
Net loss											$ 0											0											(18,645)																		$ (18,645)
Issuance of common stock upon exercise of options (in shares)																																																			0
Balances (in shares) at Dec. 31, 2019											48,254,994
Balances at Dec. 31, 2019											$ 5											129,608											(116,661)						$ 0												$ 12,952
Issuance of common stock, net of offering costs (in shares)					12,503,806			692,651
Issuance of common stock, net of offering costs					$ 1			$ 0								$ 97,033			$ 4,900								$ 0			$ 0						$ 0	$ 0							$ 97,034			$ 4,900
Issuance of common stock warrants to placement agents’ designees	$ 0											$ 453											$ 0											$ 0						$ 453
Issuance of common stock, pre-funded warrants and common stock warrants, net of offering costs (in shares)		4,000,000
Issuance of common stock, pre-funded warrants and common stock warrants, net of offering costs		$ 0											$ 8,722											$ 0											$ 0						$ 8,722
Issuance of common stock upon exercise of common stock warrants (in shares)											44,404,966
Issuance of common stock upon exercise of common stock warrants											$ 5											25,946											0						0												25,951
Stock-based compensation											0											4,358											0						0												4,358
Net loss											$ 0											0											(32,220)						0												$ (32,220)
Issuance of common stock upon exercise of options (in shares)											414,676																																								414,676
Issuance of common stock upon exercise of options											$ 0											602											0						0												$ 602
Disgorgement of short-swing profits, net of costs											$ 0											652											0						0												652
Balances (in shares) at Dec. 31, 2020											110,271,093
Balances at Dec. 31, 2020											$ 11											272,274											(148,881)						0												123,404
Issuance of common stock, net of offering costs (in shares)									13,239,839																																								13,239,839
Issuance of common stock, net of offering costs									$ 2											$ 122,208											$ 0							$ 0										$ 122,210
Issuance of common stock upon exercise of pre-funded warrants (in shares)											1,070,921
Issuance of common stock upon exercise of pre-funded warrants											$ 0											1,745											0						0												1,745
Issuance of common stock upon exercise of common stock warrants (in shares)											1,012,540
Issuance of common stock upon exercise of common stock warrants											$ 0											1,849											0						0												1,849
Stock-based compensation											0											8,867											0						0												8,867
Net loss											0											0											(70,470)						0												$ (70,470)
Issuance of common stock upon exercise of options (in shares)																																																			1,070,921
Unrealized losses on available-for-sale investments											$ 0											0											0						(74)												$ (74)
Balances (in shares) at Dec. 31, 2021											125,594,393
Balances at Dec. 31, 2021											$ 13											$ 406,943											$ (219,351)						$ (74)												$ 187,531

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Equity (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
The March 2020 Offering [Member]
Offering costs		$ 1,278
The September 2019 Offering [Member]
Offering costs			$ 1,579
The July 2020 Offering [Member]
Offering costs		2,966
The April 2019 Offering [Member]
Offering costs			1,459
The December 2020 Offering [Member]
Offering costs		$ 563
The October 2020 Offering [Member] | Underwriters' Designees [Member]
Offering costs	$ 5,752
Offering costs			$ 560

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (70,470,000)	$ (32,220,000)	$ (18,645,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,208,000	2,710,000	3,596,000
Gain on sale of equipment	0	0	(1,000)
Accretion of premium on investments	85,000	0	0
Impairment of property and equipment and right-of-use assets	0	0	1,272,000
Impairment of intangible assets	3,005,000	0	0
Stock-based compensation	8,867,000	4,358,000	627,000
Non-cash interest expense	0	0	88,000
Gain on remeasurement of future royalty liability	(3,789,000)	0	0
Loss on debt extinguishment	0	0	100,000
Non-cash interest expense related to sale of future royalties	1,480,000	1,874,000	2,073,000
Non-cash revenue related to sale of future royalties	(1,098,000)	(3,277,000)	(3,482,000)
Change in operating assets and liabilities:
Accounts receivable	263,000	3,285,000	(1,823,000)
Prepaid expenses and other assets	(1,800,000)	(1,108,000)	855,000
Accounts payable	1,626,000	1,207,000	(62,000)
Accrued liabilities	(2,209,000)	(579,000)	2,312,000
Net cash used in operating activities	(59,832,000)	(23,750,000)	(13,090,000)
Cash flows from investing activities:
Purchase of property and equipment	(5,157,000)	(1,223,000)	(850,000)
Proceeds from sale of equipment	0	3,000	0
Purchases of investments	(44,811,000)	0	0
Proceeds from maturities of investments	5,700,000	0	0
Net cash used in investing activities	(49,097,000)	(1,220,000)	(850,000)
Cash flows from financing activities:
Net proceeds from issuance of common stock in registered direct offerings	0	9,175,000	2,540,000
Proceeds from issuance of common stock upon exercise of pre-funded warrants	0	0	1,226,000
Proceeds from issuance of common stock upon exercise of common stock warrants	1,849,000	25,951,000	180,000
Proceeds from issuance of common stock upon exercise of stock options	1,745,000	602,000	0
Disgorgement of short-swing profits, net of costs	0	652,000	0
Repayment of principal on secured promissory note payable to Oxford Finance	0	0	(3,799,000)
Net cash provided by financing activities	125,804,000	138,314,000	15,960,000
Net increase in cash and cash equivalents	16,875,000	113,344,000	2,020,000
Cash and cash equivalents at beginning of the period	126,870,000	13,526,000	11,506,000
Cash and cash equivalents at end of the period	143,745,000	126,870,000	13,526,000
Supplemental disclosure of cash flow information:
Interest paid	0	0	227,000
Supplemental disclosure of non-cash investing and financing activity:
Issuance of warrants to placement agents’ designees	0	453,000	100,000
Issuance of warrants to underwriters’ designees	0	0	830,000
Operating lease liabilities arising from obtaining right-of-use assets	8,395,000	5,664,000	1,929,000
Property and equipment acquired as an incentive to enter an operating lease	0	87,000	0
Lease-related assets and liabilities derecognized on early termination and modification of leases	321,000	0	0
Acquisition of property and equipment included in accounts payable and accrued expenses	453,000	78,000	4,000
Proceeds due for sale of property and equipment included in prepaid expenses and other current assets	0	0	3,000
ATM Program [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock in registered direct offerings	122,210,000	101,934,000	0
The April 2019 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock, pre-funded warrants and common warrants in underwritten offering	0	0	8,074,000
The September 2019 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock, pre-funded warrants and common warrants in underwritten offering	0	0	7,739,000
Kindred BioSciences GMP Line Acquisition [Member]
Cash flows from investing activities:
Acquisition of business	$ (4,829,000)	$ 0	$ 0

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. General Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, July 2007, February 2018, On March 20, 2019, “March 2019 March 2019 five March 2019 11 December 31, 2021, March 2019 On April 11, 2019, “April 2019 five Pursuant to the terms of an underwriting agreement, the Company paid the underwriters aggregate commissions and reimbursable costs of $750,000. In addition, the Company issued the underwriters’ designees 636,364 common stock warrants at the closing of the April 2019 five 11 The total gross proceeds from the April 2019 December 31, 2021, April 2019 On September 30, 2019, “September 2019 3,558,161 4,000,000 five Pursuant to the terms of an underwriting agreement, the Company paid the underwriters aggregate commissions and reimbursable costs of $713,000. In addition, the Company issued the underwriters’ designees 2,115,738 common stock warrants at the closing of the September 2019 five 11 The total gross proceeds from the September 2019 December 31, 2021, September 2019 On March 2, 2020, “March 2020 five March 2020 five March 2020 11 The total gross proceeds from the March 2020 December 31, 2021, March 2020 On June 8, 2020, On July 13, 2020, July 8, 2020. On October 13, 2020, “October 2020 October 13, 2020, December 31, 2020, October 2020 2020. In the year ended December 31, 2021, October 2020 October 2020 December 31, 2021, October 2020 On September 13, 2021, October 2020 September 15, 2021, “September 2021 may September 16, 2021, December 31, 2021, September 2021 The Company’s principal operations are based in South San Francisco, California, and it operates in one

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation Basis of Consolidation Use of Estimates Foreign Currencies no Cash and Cash Equivalents three may Investments may three The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. Marketable debt securities are classified and accounted for as available-for-sale. After consideration of the Company’s objectives to preserve capital, as well as its liquidity requirements, it may 12 12 12 12 Securities are evaluated for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, including whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not Concentration of Credit Risk not The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one Accounts Receivable 2019, 6 no December 31, 2021 2020 Property and Equipment The useful lives of the property and equipment are as follows: Laboratory equipment (in years) 5 Office and computer equipment (in years) 3 Leasehold improvements Shorter of remaining lease term or estimated useful life Goodwill and Other Intangible Assets not Impairment of Long-Lived Assets fourth may not December 31, 2019 ( 14 December 31, 2021 ( 5 Accrued Clinical and Manufacturing Expenses third not The Company estimates the amount of services provided through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. The Company makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, it adjusts its accrued estimates. Although the Company does not may third not Leases one not not Revenue Recognition five (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. Revenue from royalties earned as a percentage of sales, including milestone payments based on achieving a specified level of sales, where a license is deemed to be the predominant item to which the royalties relate, is recognized as revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as required under the sales- and usage-based royalty exception. Revenue from contracts with customers is recognized ratably, based on costs incurred, as the Company provides promised services to its customers in amounts that reflect the consideration that the Company expects to receive for those services. The Company performed research and development work under its cost-plus-fixed-fee contract with HHS BARDA. The Company recognizes revenue under research contracts only when a contract has been executed and the contract price is fixed or determinable. Revenue from the HHS BARDA contract is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable conditions under the contract have been met. Costs of contract revenue are recorded as a component of operating expenses in the consolidated statements of operations and comprehensive loss. Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned. Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Payments to the Company under cost reimbursable contracts, such as this contract, are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not may Research and Development Costs third Stock-Based Compensation Net Income (Loss) Per Share Diluted net income (loss) per common share is computed giving effect to all potential dilutive common shares, comprising common stock issuable upon exercise of stock options and warrants. The Company uses the treasury-stock method to compute diluted income (loss) per share with respect to its stock options and warrants. For purposes of this calculation, options and warrants to purchase common stock are considered to be potential common shares and are only included in the calculation of diluted net income per share when their effect is dilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive. Reclassification Prior year data is subject to reclassification to conform to current year presentation. Recently Adopted Accounting Pronouncements In August 2020, 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 815 40 none January 1, 2021. Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not not not

Note 3 - Business Combination

Note 3 - Business Combination	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 3. On November 30, 2021, The fair value of the assets acquired in connection with the acquisition are as follows (in thousands): Property and equipment $ 321 Goodwill 4,508 Total purchase price $ 4,829 In addition, the Company paid $671,000 in prepaid rent in connection with the modification of the pre-existing embedded lease at the Burlingame facility (see Note 8 Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, is attributable primarily to the expected cost savings of manufacturing internally, as opposed to outsourcing, and the assembled workforce. All of the goodwill is expected to be deductible for income tax purposes.

Note 4 - Fair Value of Financia

Note 4 - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 4. Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three The three Level 1 Level 2 not Level 3 no The following table sets forth the fair value of the Company’s financial assets that are measured on a recurring basis as of December 31, 2021 2020 Level 1 Level 2 Level 3 Total December 31, 2021 Recurring financial assets: Money market funds $ 70,978 $ — $ — $ 70,978 U.S. Treasury securities — 24,997 — 24,997 Commercial paper — 7,491 — 7,491 Corporate debt securities — 6,464 — 6,464 Total assets $ 70,978 $ 38,952 $ — $ 109,930 Level 1 Level 2 Level 3 Total December 31, 2020 Recurring financial assets: Money market funds $ 60,005 $ — $ — $ 60,005 Total assets $ 60,005 $ — $ — $ 60,005 The Company held no financial liabilities measured on a recurring basis as of December 31, 2021 2020, December 31, 2021, 2020 2019.

Note 5 - Balance Sheet Componen

Note 5 - Balance Sheet Components	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	NOTE 5. (a) Cash, Cash Equivalents and Investments Cash, cash equivalents and investments consisted of the following (in thousands): Amortized Gross Unrealized Estimated Cash and Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments December 31, 2021 Cash at banks $ 72,767 $ — $ — $ 72,767 $ 72,767 $ — $ — Money market funds 70,978 — — 70,978 70,978 — — U.S. Treasury securities 25,055 — (58 ) 24,997 — 12,022 12,975 Commercial paper 7,491 — — 7,491 — 7,491 — Corporate debt securities 6,480 — (16 ) 6,464 — 3,229 3,235 Total $ 182,771 $ — $ (74 ) $ 182,697 $ 143,745 $ 22,742 $ 16,210 Amortized Gross Unrealized Estimated Cash and Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments December 31, 2020 Cash at banks $ 66,865 $ — $ — $ 66,865 $ 66,865 $ — $ — Money market funds 60,005 — — 60,005 60,005 — — Total $ 126,870 $ — $ — $ 126,870 $ 126,870 $ — $ — (b) Accounts Receivable Accounts receivable comprises royalties receivable of $71,000 and $334,000 as of December 30, 2021 2020, (c) Property and Equipment, Net Property and equipment, net consists of the following (in thousands): December 31, 2021 December 31, 2020 Laboratory equipment $ 5,057 $ 1,759 Office and computer equipment 481 294 Leasehold improvements 1,063 — Construction in progress 1,305 — Total property and equipment 7,906 2,053 Less: accumulated depreciation (1,305 ) (573 ) Property and equipment, net $ 6,601 $ 1,480 Depreciation expense was $732,000, $114,000 and $504,000 for the years ended December 31, 2021, 2020 2019 one 14 December 31, 2019, (d) Right-of-Use Assets, Net Right-of-use assets consist of the following (in thousands): December 31, 2021 December 31, 2020 Facilities $ 13,168 $ 6,836 Office equipment — 2 Right-of-use assets, net $ 13,168 $ 6,838 The right of use of one 14 December 31, 2019, (e) Intangible Assets, Net Intangible assets comprise developed technology, intellectual property and, until it was considered fully impaired, in-process research and development. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives ranging from 1.3 to 11.75 years for developed technology and 20 years for intellectual property. As of December 31, 2021, December 31, 2021 December 31, 2020 Developed technology $ 10,600 $ 20,300 Intellectual property 80 80 Total cost 10,680 20,380 Less: accumulated amortization (56 ) (5,019 ) Intangible assets, net $ 10,624 $ 15,361 Intangible asset amortization expense was $1.7 million, $1.7 million and $2.3 million for the years ended December 31, 2021, 2020 2019 19 7 December 31, 2021, As of December 31, 2021 Year Ending December 31, Amount 2022 $ 1,350 2023 1,350 2024 1,350 2025 1,350 2026 1,350 Thereafter 3,874 Total $ 10,624 (f) Other Accrued Liabilities Other accrued liabilities consist of the following (in thousands): December 31, 2021 December 31, 2020 Accrued compensation $ 2,786 $ 1,618 Accrued clinical and manufacturing expenses 986 1,772 Accrued professional and consulting services 556 777 Other liabilities, current portion 736 632 Total $ 5,064 $ 4,799

Note 6 - Revenue

Note 6 - Revenue	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Revenue [Text Block]	NOTE 6. Service Contracts with Customers Contract Balances. December 31, 2021 2020. December 31, 2021 2020, nil Remaining Performance Obligations. December 31, 2021 2020, no nil not not not U.S. Government HHS BARDA Contract In September 2015, May 25 July 18, 2017, June 28, 2018, September 30, 2018. December 31, 2021 no Billings under the contract are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, overhead and general and administrative expenses. Indirect rates as well as allowable costs are subject to audit by HHS BARDA on an annual basis. Management believes that revenues recognized to date have been recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may three December 31, 2019, 2018 may not December 31, 2021, Royalty agreements Aviragen entered into a royalty-bearing research and license agreement with GlaxoSmithKline, plc (“GSK”) in 1990 July 2019 2021, 2020 2019, nil, The Company also generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), in 2009. September 2010, December 2029 2021, 2020 2019, nil, 7 2021, 2020 2019, December 31, 2021, 2020 2019,

Note 7 - Liabilities Related to

Note 7 - Liabilities Related to Sale of Future Royalties	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Liabilities Related to Sale of Future Royalties [Text Block]	NOTE 7. Liabilities Related to Sale of Future Royalties In April 2016, first April 1, Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction was accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. The Company has no not not The following table shows the activity within the liability account during the year ended December 31, 2021 ( Total liability related to sale of future royalties, start of year $ 14,929 Non-cash royalty revenue paid to HCRP (1,098 ) Non-cash interest expense recognized 1,480 Revaluation gain recognized (3,789 ) Total liability related to sale of future royalties, end of year 11,522 Current portion (836 ) Long-term portion $ 10,686 Due to a decline in royalties earned since the outbreak of COVID- 19, December 31, 2021,

Note 8 - Leases

Note 8 - Leases	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 8. The Company has obtained the right of use for office and manufacturing facilities under five one The Company obtained the right of use of real estate located in South San Francisco, California, in November 2020 September 30, 2025, March 31, 2029, no June 2015 April 30, 2020, five July 2019, April 30, 2025, March 31, 2029, eight December 31, 2019 ( 14 one July 31, 2022, no March 30, 2029, five September 2022. May 31, 2025, 3 February 2018, February 28, 2021, no November 30, 2018. As of December 31, 2021, one The following table summarizes the Company’s undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than twelve December 31, 2021 ( Year Ending December 31, Amount 2022 $ 2,071 2023 2,123 2024 2,195 2025 2,297 2026 2,852 Thereafter 6,770 Undiscounted total 18,308 Less: imputed interest (5,300 ) Present value of future minimum payments 13,008 Current portion of operating lease liability (1,011 ) Operating lease liability, net of current portion $ 11,997 The Company presently has no finance leases and future obligations of $14,000 for facilities and $8,000 for equipment under operating leases with initial terms of one Certain operating lease agreements for facilities include non-lease costs, such as common area maintenance, which are recorded as variable lease costs. Operating lease expenses for the years ended December 31, 2021 2020 2019, Year Ended December 31, 2021 2020 2019 Lease cost Operating lease cost $ 2,513 $ 1,145 $ 959 Short-term lease cost 340 13 15 Variable lease cost 1,233 264 162 Sublease income (36 ) (217 ) (217 ) Total lease cost $ 4,050 $ 1,205 $ 919 Net cash outflows associated with operating leases totaled $4.4 million, $1.1 million and $983,000 in the years ended December 31, 2021, 2020 2019,

Note 9 - Secured Promissory Not

Note 9 - Secured Promissory Note Payable to Oxford Finance	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Secured Promissory Note Payable [Text Block]	NOTE 9. On December 22, 2016, $5.0 30 four first 12 36 In conjunction with the execution of the Loan Agreement, all the holders of convertible promissory notes signed subordination agreements, under which they agreed to subordinate in favor of Oxford Finance all amounts due under their promissory notes and any security interest in the Company’s property. In addition, the holders of the notes agreed that they would not In connection with the Loan Agreement, the Company issued a warrant to Oxford Finance to purchase 7,563 shares of its Series C convertible preferred stock at an exercise price of $33.11 per share (the “Warrant”). The fair value of the Warrant at the date of issuance was approximately $134,000 which, along with other initial costs, was recorded as debt discount and was amortized as interest expense over the term of the loan using the effective-interest method. Due to the antidilution protection, following the Merger, the Warrant was amended to allow the holder to purchase 10,914 shares of common stock at an exercise price of $22.99 per share. The annual effective interest rate of the note, including the accretion of the final payment and the amortization of the debt discount, was approximately 10.5%. The Company recorded interest expense related to the Loan Agreement of $311,000 during the year ended December 31, 2019, November 4, 2019.

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 10. (a) Purchase Commitments As of December 31, 2021 eighteen Note 8 March 31, 2029, not (b) Indemnifications In the ordinary course of business, the Company enters into agreements that may may third not may (c) From time to time the Company may not On August 4, 2020, Godfrey v. Latour, et al. September 4, 2020 Ennis v. Latour, et al second November 25, 2020. March 15, 2021, second third June 11, 2021. third third June 2020; April 24, 2020, two June 8, 2020. third no August 31, 2021, third not On September 8, 2020, Galjour v. Floroiu, et al. October 20, 2020, Jaquith v. Vaxart, Inc. November 12, 2020, two In re Vaxart, Inc. Stockholder Litigation March 24, 2020 June 15, 2020; April 24, 2020, two June 8, 2020. one one April 24, 2020, no January 4, 2021, November 30, 2021 December 1, 2021, not In August September 2020, two first Himmelberg v. Vaxart, Inc. et al. August 24, 2020. second Hovhannisyan v. Vaxart, Inc. et al. September 1, 2020 ( September 17, 2020, two December 9, 2020, January 29, 2021, July 8, 2021, May 14, 2021, June 10, 2021, August 9, 2021, three 10 10b 5, 20 20A first July 8, 2021, first December 22, 2021, February 2, 2022, February 8, 2022, On October 23, 2020, Roth v. Armistice Capital LLC, et al. 16 On January 8, 2021, pro se Chan v. Vaxart, Inc. et al. Opt-Out Action On March 5, 2021, June 2, 2021, February 10, 2022, No not not may

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 11. (a) Convertible Preferred Stock The Company is authorized to issue 5,000,000 shares of preferred stock, $0.0001 par value per share. The Company’s board of directors may, 5,000,000 one may no (b) Common Stock Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company’s directors and all other matters requiring stockholder action. Holders of common stock are entitled to one may no December 31, 2021 In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no The Company had shares of common stock reserved for issuance as follows: December 31, 2021 December 31, 2020 Options issued and outstanding 10,216,106 6,813,033 Available for future grants of equity awards 5,582,742 1,230,863 Common stock warrants 232,434 1,244,974 Total 16,031,282 9,288,870 (c) Warrants The Company has the following warrants outstanding as of December 31, 2021 none Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 5,000 $ 0.30 September 2024 Common Stock 44,148 $ 1.10 April 2024 Common Stock 26,515 $ 1.375 April 2024 Common Stock 29,150 $ 2.50 March 2025 Common Stock 100,532 $ 3.125 February 2025 Common Stock 16,175 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 232,434 The aggregate fair value at issuance of the warrants issued to the placement agents’ designees at the closing of the March 2019 March 2020 April 2019 September 2019 1 Offering March 2019 April 2019 September 2019 March 2020 Aggregate valuation on issuance date $ 100,000 $ 333,000 $ 497,000 $ 453,000 Number of warrants issued 84,000 636,364 2,115,738 280,000 Exercise price $ 3.125 $ 1.375 $ 0.375 $ 3.125 Closing stock price $ 2.08 $ 0.89 $ 0.36 $ 2.34 Risk-free interest rate 2.34 % 2.31 % 1.55 % 0.88 % Expected term (in years) 5.00 5.00 5.00 4.99 Expected volatility 80 % 83 % 83 % 98 % Dividend yield — % — % — % — % In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company’s control, the holders of the unexercised common stock warrants exercisable for $0.30, $1.10 and $2.50 and those exercisable for $3.125 expiring in February 2025 not

Note 12 - Equity Incentive Plan

Note 12 - Equity Incentive Plans	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 12. On April 23, 2019, 2019 “2019 may 2019 may 2019 not 2019 The aggregate number of shares of common stock authorized for issuance under the 2019 2019 June 8, 2020, June 16, 2021, 2019 2019 ten may A summary of stock option transactions in each of the three December 31, 2021 Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2019 200,650 865,163 $ 8.13 Authorized under 2019 Plan on Adoption 1,600,000 — $ — Removed from 2016 Plan (223,389 ) — $ — Granted (1,791,030 ) 1,791,030 $ 0.67 Forfeited 483,849 (592,528 ) $ 1.57 Canceled 25,100 (252,013 ) $ 9.25 Balance at December 31, 2019 295,180 1,811,652 $ 2.74 Authorized under 2019 Plan Amendment 6,400,000 — $ — Granted (5,579,800 ) 5,579,800 $ 2.66 Exercised — (414,676 ) $ 1.45 Forfeited 105,910 (105,992 ) $ 1.65 Canceled 9,573 (57,751 ) $ 10.57 Balance at December 31, 2020 1,230,863 6,813,033 $ 2.70 Authorized under 2019 Plan Amendment 8,900,000 — $ — Granted (5,178,438 ) 5,178,438 $ 7.09 Exercised — (1,070,921 ) $ 1.63 Forfeited 630,317 (650,054 ) $ 3.16 Canceled — (54,390 ) $ 11.98 Balance at December 31, 2021 5,582,742 10,216,106 $ 4.96 As of December 31, 2021 The aggregate intrinsic value represents the total pre-tax value (i.e., the difference between the Company’s stock price and the exercise price) of stock options outstanding as of December 31, 2021 The Company received $1.7 million for the 1,070,921 options exercised during the year ended December 31, 2021, December 31, 2020, December 31, 2019 On June 15, 2020, ten November 30, 2020, third third third November 30, 2020, July 9, 2020, July 20, 2020 July 24, 2020, June 30, 2020, three September 30, 2020. Excluding these performance-based options, the weighted average grant date fair value of options awarded in the years ended December 31, 2021, 2020 2019 Year Ended December 31, 2021 2020 2019 Risk-free interest rate 0.91% - 1.35% 0.40% - 0.88% 1.68% - 2.31% Expected term (in years) 5.44 - 6.08 5.22 - 10.00 5.39 - 10.00 Expected volatility 122% - 131% 94% - 111% 83% - 85% Dividend yield — % — % — % The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options was as follows (in thousands): Year Ended December 31, 2021 2020 2019 Research and development $ 4,304 $ 1,563 $ 253 General and administrative 4,563 2,795 374 Total stock-based compensation $ 8,867 $ 4,358 $ 627 Effective June 16, 2021, three ten June 16, 2023. three June 30, 2021. As of December 31, 2021

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 13. In April 2020, 16 1934,

Note 14 - Restructuring Charges

Note 14 - Restructuring Charges (Reversals)	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	NOTE 14. Restructuring liabilities primarily consisted of the estimated future obligations for contract suspension costs and severance and benefits obligations. These restructuring liabilities, all of which were paid in the year ending December 31, 2020, The Company approved a reduction-in-force during the year ended December 31, 2019, three March 31, 2020. September 2020 no December 31, 2020, December 31, 2021, not Cumulative restructuring costs incurred and a reconciliation of the change in related liabilities during the years ended December 31, 2019 2020, Suspension Severance Impairment of Contract Benefits Charges Other Total Cumulative cost incurred as of December 31, 2021 $ 2,252 $ 368 $ 1,272 $ 179 $ 4,071 Reconciliation of liabilities: Balance at January 1, 2019 $ — $ — $ — $ — $ — Period charges 3,223 368 1,272 57 4,920 Settlements — — (1,272 ) — (1,272 ) Balance at December 31, 2019 3,223 368 — 57 3,648 Period charges — — — 122 122 Period reversals (971 ) — — — (971 ) Settlements (2,252 ) (368 ) — (179 ) (2,799 ) Balance at December 31, 2020 $ — $ — $ — $ — $ — There was no restructuring liability as of December 31, 2021.

Note 15 - Benefit Plan

Note 15 - Benefit Plan	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 15. The Company provides a tax-qualified employee savings and retirement plan commonly known as a 401 may $19,500 2021 2020, $19,000 2019. 50 may $6,500 2021 2020, $6,000 2019. Employees direct their contributions, which vest immediately, across a series of mutual funds. In the years ended December 31, 2021, 2020 2019, December 31, 2021, 2020 2019, December 31, 2021, 2020 2019,

Note 16 - Income Taxes

Note 16 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 16. The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2021 2020 2019 Current: Federal $ — $ — $ — State 1 3 2 Foreign 106 235 488 Total Current 107 238 490 Deferred: Federal — — — State — — — Foreign — — — Total Deferred — — — Provision for income taxes $ 107 $ 238 $ 490 The components of the deferred tax assets are as follows (in thousands): December 31, 2021 December 31, 2020 December 31, 2019 Deferred tax assets: Net operating loss carryforwards $ 30,256 $ 14,161 $ 6,924 Research and development tax credits 4,923 2,497 1,591 Capitalized research and development 4,016 4,534 4,773 Sale of future royalties 5,826 7,178 7,486 Lease liability 3,184 1,695 492 Accruals, reserves and other 3,043 1,327 1,253 Total deferred tax assets 51,248 31,392 22,519 Valuation allowance (42,589 ) (21,952 ) (13,365 ) Deferred tax assets net of valuation allowance 8,659 9,440 9,154 Deferred tax liabilities: Intangible assets (5,410 ) (7,832 ) (8,730 ) Right-of-use assets (3,223 ) (1,608 ) (424 ) Depreciation on property and equipment (26 ) — — Total deferred tax liabilities (8,659 ) (9,440 ) (9,154 ) Net deferred tax assets $ — $ — $ — A reconciliation of the provision for income taxes with the expected provision for income taxes computed by applying the federal statutory income tax rate of 21% Year Ended December 31, 2021 2020 2019 U.S. federal taxes at statutory rate 21.0 % 21.0 % 21.0 % State taxes (net of federal benefit) 4.0 2.9 0.4 Foreign rate differential 0.3 (0.7 ) (2.6 ) Permanently non-deductible items 0.2 2.2 (3.7 ) Tax credits 3.4 2.8 1.7 Change in valuation allowance (29.3 ) (26.8 ) 194.2 Tax attributes write-off due to change in control — 0.5 (208.3 ) Prior year true-up 0.6 (2.5 ) (0.9 ) Other (0.3 ) (0.1 ) (4.5 ) Provision for income taxes (0.1 )% (0.7 )% (2.7 )% The Company’s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% for the year ended December 31, 2019, December 31, 2021, 2020 2019 As of December 31, 2021, 2020 2019 not 2024 2028 2019 As of December 31, 2021 not may not As of December 31, 2021, 2020 2019 2039, not Sections 382 383 not 382 383 not The Company is required to reduce its deferred tax assets by a valuation allowance if it is more likely than not not December 31, 2021, 2020 2019 December 31, 2021 2020, December 31, 2019. 2019 September 30, 2019. The Company records unrecognized tax benefits, where appropriate, for all uncertain income tax positions. The Company recorded unrecognized tax benefits for uncertain tax positions of approximately $2.4 million and $1.3 million as of December 31, 2021 2020 none A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2021 2020 2019 Beginning Balance $ 1,281 $ 851 $ 1,582 Additions based on tax positions related to the current year 1,132 431 159 Increase (decreases) related to prior years’ tax positions 9 (1 ) (890 ) Ending Balance $ 2,422 $ 1,281 $ 851 The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. During the years ended December 31, 2021, 2020 2019 no twelve The Company files income tax returns in the U.S. and Australia, as well as with various U.S. states. The Company is subject to tax audits in all jurisdictions in which it files income tax returns. Tax audits by their very nature are often complex and can require several years to complete. There are currently no Under the tax statute of limitations applicable to the Internal Revenue Code, the Company and its U.S. subsidiary, either standalone or as part of the consolidated group, is no 2018. no 2017 2016

Note 17 - Net Loss Per Share At

Note 17 - Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 17. The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts): Year Ended December 31, 2021 2020 2019 Net loss $ (70,470 ) $ (32,220 ) $ (18,645 ) Shares used to compute net loss per share, basic and diluted 121,453,723 88,295,762 21,569,523 Net loss per share attributable to common stockholders, basic and diluted $ (0.58 ) $ (0.36 ) $ (0.86 ) No adjustment has been made to the net loss attributable to common stockholders as the effect would be anti-dilutive due to the net loss. The following potentially dilutive securities were excluded from the computation of diluted weighted average shares outstanding because they would have been antidilutive: Year Ended December 31, 2021 2020 2019 Options to purchase common stock 8,206,137 4,409,806 1,583,575 Warrants to purchase common stock 369,043 14,773,425 17,579,945 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 8,575,180 19,183,231 19,163,520

Note 18 - Quarterly Financial D

Note 18 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Quarterly Financial Information [Text Block]	NOTE 18. Selected summarized quarterly financial information for each of the last three Year Ended December 31, 2021 First Second Third Fourth Revenue $ 506 $ 112 $ 200 $ 74 Operating expenses $ 16,017 $ 15,887 $ 17,451 $ 24,289 Net loss $ (16,007 ) $ (16,116 ) $ (17,583 ) $ (20,764 ) Net loss per share – basic and diluted $ (0.14 ) $ (0.13 ) $ (0.14 ) $ (0.17 ) Year Ended December 31, 2020 First Second Third Fourth Revenue $ 2,902 $ 523 $ 265 $ 356 Operating expenses $ 3,596 $ 9,049 $ 7,854 $ 13,717 Net loss $ (1,297 ) $ (8,977 ) $ (8,085 ) $ (13,861 ) Net loss per share – basic and diluted $ (0.02 ) $ (0.12 ) $ (0.08 ) $ (0.13 ) Year Ended December 31, 2019 First Second Third Fourth Revenue $ 5,407 $ 85 $ 454 $ 3,916 Operating expenses $ 5,855 $ 5,082 $ 5,168 $ 9,542 Net loss $ (1,339 ) $ (5,637 ) $ (5,260 ) $ (6,409 ) Net loss per share – basic and diluted $ (0.18 ) $ (0.39 ) $ (0.32 ) $ (0.13 )

Note 19 - Subsequent Events

Note 19 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 19. Since December 31, 2021, September 2021 1 Changes in the status of litigation since December 31, 2021, 10. Litigation

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
Consolidation, Policy [Policy Text Block]	Basis of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currencies no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents three may
Investment, Policy [Policy Text Block]	Investments may three The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. Marketable debt securities are classified and accounted for as available-for-sale. After consideration of the Company’s objectives to preserve capital, as well as its liquidity requirements, it may 12 12 12 12 Securities are evaluated for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, including whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk not The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one
Receivable [Policy Text Block]	Accounts Receivable 2019, 6 no December 31, 2021 2020
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment The useful lives of the property and equipment are as follows: Laboratory equipment (in years) 5 Office and computer equipment (in years) 3 Leasehold improvements Shorter of remaining lease term or estimated useful life
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Goodwill and Other Intangible Assets not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets fourth may not December 31, 2019 ( 14 December 31, 2021 ( 5
Accrued Clinical And Manufacturing Expenses Policy [Policy Text Block]	Accrued Clinical and Manufacturing Expenses third not The Company estimates the amount of services provided through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. The Company makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, it adjusts its accrued estimates. Although the Company does not may third not
Lessee, Leases [Policy Text Block]	Leases one not not
Revenue [Policy Text Block]	Revenue Recognition five (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account. Revenue from royalties earned as a percentage of sales, including milestone payments based on achieving a specified level of sales, where a license is deemed to be the predominant item to which the royalties relate, is recognized as revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as required under the sales- and usage-based royalty exception. Revenue from contracts with customers is recognized ratably, based on costs incurred, as the Company provides promised services to its customers in amounts that reflect the consideration that the Company expects to receive for those services. The Company performed research and development work under its cost-plus-fixed-fee contract with HHS BARDA. The Company recognizes revenue under research contracts only when a contract has been executed and the contract price is fixed or determinable. Revenue from the HHS BARDA contract is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable conditions under the contract have been met. Costs of contract revenue are recorded as a component of operating expenses in the consolidated statements of operations and comprehensive loss. Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned. Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Payments to the Company under cost reimbursable contracts, such as this contract, are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not may
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs third
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) Per Share Diluted net income (loss) per common share is computed giving effect to all potential dilutive common shares, comprising common stock issuable upon exercise of stock options and warrants. The Company uses the treasury-stock method to compute diluted income (loss) per share with respect to its stock options and warrants. For purposes of this calculation, options and warrants to purchase common stock are considered to be potential common shares and are only included in the calculation of diluted net income per share when their effect is dilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification Prior year data is subject to reclassification to conform to current year presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In August 2020, 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 815 40 none January 1, 2021. Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not not not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Property, Plant, and Equipment, Useful Life [Table Text Block]	Laboratory equipment (in years) 5 Office and computer equipment (in years) 3 Leasehold improvements Shorter of remaining lease term or estimated useful life

Note 3 - Business Combination (

Note 3 - Business Combination (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Property and equipment $ 321 Goodwill 4,508 Total purchase price $ 4,829

Note 4 - Fair Value of Financ_2

Note 4 - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total December 31, 2021 Recurring financial assets: Money market funds $ 70,978 $ — $ — $ 70,978 U.S. Treasury securities — 24,997 — 24,997 Commercial paper — 7,491 — 7,491 Corporate debt securities — 6,464 — 6,464 Total assets $ 70,978 $ 38,952 $ — $ 109,930 Level 1 Level 2 Level 3 Total December 31, 2020 Recurring financial assets: Money market funds $ 60,005 $ — $ — $ 60,005 Total assets $ 60,005 $ — $ — $ 60,005

Note 5 - Balance Sheet Compon_2

Note 5 - Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	Amortized Gross Unrealized Estimated Cash and Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments December 31, 2021 Cash at banks $ 72,767 $ — $ — $ 72,767 $ 72,767 $ — $ — Money market funds 70,978 — — 70,978 70,978 — — U.S. Treasury securities 25,055 — (58 ) 24,997 — 12,022 12,975 Commercial paper 7,491 — — 7,491 — 7,491 — Corporate debt securities 6,480 — (16 ) 6,464 — 3,229 3,235 Total $ 182,771 $ — $ (74 ) $ 182,697 $ 143,745 $ 22,742 $ 16,210 Amortized Gross Unrealized Estimated Cash and Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments December 31, 2020 Cash at banks $ 66,865 $ — $ — $ 66,865 $ 66,865 $ — $ — Money market funds 60,005 — — 60,005 60,005 — — Total $ 126,870 $ — $ — $ 126,870 $ 126,870 $ — $ —
Property, Plant and Equipment [Table Text Block]	December 31, 2021 December 31, 2020 Laboratory equipment $ 5,057 $ 1,759 Office and computer equipment 481 294 Leasehold improvements 1,063 — Construction in progress 1,305 — Total property and equipment 7,906 2,053 Less: accumulated depreciation (1,305 ) (573 ) Property and equipment, net $ 6,601 $ 1,480
Lessee, Operating Lease, Right-of-Use Assets [Table Text Block]	December 31, 2021 December 31, 2020 Facilities $ 13,168 $ 6,836 Office equipment — 2 Right-of-use assets, net $ 13,168 $ 6,838
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2021 December 31, 2020 Developed technology $ 10,600 $ 20,300 Intellectual property 80 80 Total cost 10,680 20,380 Less: accumulated amortization (56 ) (5,019 ) Intangible assets, net $ 10,624 $ 15,361
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ending December 31, Amount 2022 $ 1,350 2023 1,350 2024 1,350 2025 1,350 2026 1,350 Thereafter 3,874 Total $ 10,624
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2021 December 31, 2020 Accrued compensation $ 2,786 $ 1,618 Accrued clinical and manufacturing expenses 986 1,772 Accrued professional and consulting services 556 777 Other liabilities, current portion 736 632 Total $ 5,064 $ 4,799

Note 7 - Liabilities Related _2

Note 7 - Liabilities Related to Sale of Future Royalties (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Total liability related to sale of future royalties, start of year $ 14,929 Non-cash royalty revenue paid to HCRP (1,098 ) Non-cash interest expense recognized 1,480 Revaluation gain recognized (3,789 ) Total liability related to sale of future royalties, end of year 11,522 Current portion (836 ) Long-term portion $ 10,686

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, Amount 2022 $ 2,071 2023 2,123 2024 2,195 2025 2,297 2026 2,852 Thereafter 6,770 Undiscounted total 18,308 Less: imputed interest (5,300 ) Present value of future minimum payments 13,008 Current portion of operating lease liability (1,011 ) Operating lease liability, net of current portion $ 11,997
Lease, Cost [Table Text Block]	Year Ended December 31, 2021 2020 2019 Lease cost Operating lease cost $ 2,513 $ 1,145 $ 959 Short-term lease cost 340 13 15 Variable lease cost 1,233 264 162 Sublease income (36 ) (217 ) (217 ) Total lease cost $ 4,050 $ 1,205 $ 919

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Common Stock Reserved for Issuance [Table Text Block]	December 31, 2021 December 31, 2020 Options issued and outstanding 10,216,106 6,813,033 Available for future grants of equity awards 5,582,742 1,230,863 Common stock warrants 232,434 1,244,974 Total 16,031,282 9,288,870
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Securities into which warrants are convertible Warrants outstanding Exercise Price Expiration Date Common Stock 5,000 $ 0.30 September 2024 Common Stock 44,148 $ 1.10 April 2024 Common Stock 26,515 $ 1.375 April 2024 Common Stock 29,150 $ 2.50 March 2025 Common Stock 100,532 $ 3.125 February 2025 Common Stock 16,175 $ 3.125 March 2024 Common Stock 10,914 $ 22.99 December 2026 Total 232,434
Fair Value of Warrants, Assumptions [Table Text Block]	Offering March 2019 April 2019 September 2019 March 2020 Aggregate valuation on issuance date $ 100,000 $ 333,000 $ 497,000 $ 453,000 Number of warrants issued 84,000 636,364 2,115,738 280,000 Exercise price $ 3.125 $ 1.375 $ 0.375 $ 3.125 Closing stock price $ 2.08 $ 0.89 $ 0.36 $ 2.34 Risk-free interest rate 2.34 % 2.31 % 1.55 % 0.88 % Expected term (in years) 5.00 5.00 5.00 4.99 Expected volatility 80 % 83 % 83 % 98 % Dividend yield — % — % — % — %

Note 12 - Equity Incentive Pl_2

Note 12 - Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Shares Number of Average Available Options Exercise For Grant Outstanding Price Balance at January 1, 2019 200,650 865,163 $ 8.13 Authorized under 2019 Plan on Adoption 1,600,000 — $ — Removed from 2016 Plan (223,389 ) — $ — Granted (1,791,030 ) 1,791,030 $ 0.67 Forfeited 483,849 (592,528 ) $ 1.57 Canceled 25,100 (252,013 ) $ 9.25 Balance at December 31, 2019 295,180 1,811,652 $ 2.74 Authorized under 2019 Plan Amendment 6,400,000 — $ — Granted (5,579,800 ) 5,579,800 $ 2.66 Exercised — (414,676 ) $ 1.45 Forfeited 105,910 (105,992 ) $ 1.65 Canceled 9,573 (57,751 ) $ 10.57 Balance at December 31, 2020 1,230,863 6,813,033 $ 2.70 Authorized under 2019 Plan Amendment 8,900,000 — $ — Granted (5,178,438 ) 5,178,438 $ 7.09 Exercised — (1,070,921 ) $ 1.63 Forfeited 630,317 (650,054 ) $ 3.16 Canceled — (54,390 ) $ 11.98 Balance at December 31, 2021 5,582,742 10,216,106 $ 4.96
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2021 2020 2019 Risk-free interest rate 0.91% - 1.35% 0.40% - 0.88% 1.68% - 2.31% Expected term (in years) 5.44 - 6.08 5.22 - 10.00 5.39 - 10.00 Expected volatility 122% - 131% 94% - 111% 83% - 85% Dividend yield — % — % — %
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2021 2020 2019 Research and development $ 4,304 $ 1,563 $ 253 General and administrative 4,563 2,795 374 Total stock-based compensation $ 8,867 $ 4,358 $ 627

Note 14 - Restructuring Charg_2

Note 14 - Restructuring Charges (Reversals) (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Suspension Severance Impairment of Contract Benefits Charges Other Total Cumulative cost incurred as of December 31, 2021 $ 2,252 $ 368 $ 1,272 $ 179 $ 4,071 Reconciliation of liabilities: Balance at January 1, 2019 $ — $ — $ — $ — $ — Period charges 3,223 368 1,272 57 4,920 Settlements — — (1,272 ) — (1,272 ) Balance at December 31, 2019 3,223 368 — 57 3,648 Period charges — — — 122 122 Period reversals (971 ) — — — (971 ) Settlements (2,252 ) (368 ) — (179 ) (2,799 ) Balance at December 31, 2020 $ — $ — $ — $ — $ —

Note 16 - Income Taxes (Tables)

Note 16 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2021 2020 2019 Current: Federal $ — $ — $ — State 1 3 2 Foreign 106 235 488 Total Current 107 238 490 Deferred: Federal — — — State — — — Foreign — — — Total Deferred — — — Provision for income taxes $ 107 $ 238 $ 490
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2021 December 31, 2020 December 31, 2019 Deferred tax assets: Net operating loss carryforwards $ 30,256 $ 14,161 $ 6,924 Research and development tax credits 4,923 2,497 1,591 Capitalized research and development 4,016 4,534 4,773 Sale of future royalties 5,826 7,178 7,486 Lease liability 3,184 1,695 492 Accruals, reserves and other 3,043 1,327 1,253 Total deferred tax assets 51,248 31,392 22,519 Valuation allowance (42,589 ) (21,952 ) (13,365 ) Deferred tax assets net of valuation allowance 8,659 9,440 9,154 Deferred tax liabilities: Intangible assets (5,410 ) (7,832 ) (8,730 ) Right-of-use assets (3,223 ) (1,608 ) (424 ) Depreciation on property and equipment (26 ) — — Total deferred tax liabilities (8,659 ) (9,440 ) (9,154 ) Net deferred tax assets $ — $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 2020 2019 U.S. federal taxes at statutory rate 21.0 % 21.0 % 21.0 % State taxes (net of federal benefit) 4.0 2.9 0.4 Foreign rate differential 0.3 (0.7 ) (2.6 ) Permanently non-deductible items 0.2 2.2 (3.7 ) Tax credits 3.4 2.8 1.7 Change in valuation allowance (29.3 ) (26.8 ) 194.2 Tax attributes write-off due to change in control — 0.5 (208.3 ) Prior year true-up 0.6 (2.5 ) (0.9 ) Other (0.3 ) (0.1 ) (4.5 ) Provision for income taxes (0.1 )% (0.7 )% (2.7 )%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2021 2020 2019 Beginning Balance $ 1,281 $ 851 $ 1,582 Additions based on tax positions related to the current year 1,132 431 159 Increase (decreases) related to prior years’ tax positions 9 (1 ) (890 ) Ending Balance $ 2,422 $ 1,281 $ 851

Note 17 - Net Loss Per Share _2

Note 17 - Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2021 2020 2019 Net loss $ (70,470 ) $ (32,220 ) $ (18,645 ) Shares used to compute net loss per share, basic and diluted 121,453,723 88,295,762 21,569,523 Net loss per share attributable to common stockholders, basic and diluted $ (0.58 ) $ (0.36 ) $ (0.86 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2021 2020 2019 Options to purchase common stock 8,206,137 4,409,806 1,583,575 Warrants to purchase common stock 369,043 14,773,425 17,579,945 Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation 8,575,180 19,183,231 19,163,520

Note 18 - Quarterly Financial_2

Note 18 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Quarterly Financial Information [Table Text Block]	Year Ended December 31, 2021 First Second Third Fourth Revenue $ 506 $ 112 $ 200 $ 74 Operating expenses $ 16,017 $ 15,887 $ 17,451 $ 24,289 Net loss $ (16,007 ) $ (16,116 ) $ (17,583 ) $ (20,764 ) Net loss per share – basic and diluted $ (0.14 ) $ (0.13 ) $ (0.14 ) $ (0.17 ) Year Ended December 31, 2020 First Second Third Fourth Revenue $ 2,902 $ 523 $ 265 $ 356 Operating expenses $ 3,596 $ 9,049 $ 7,854 $ 13,717 Net loss $ (1,297 ) $ (8,977 ) $ (8,085 ) $ (13,861 ) Net loss per share – basic and diluted $ (0.02 ) $ (0.12 ) $ (0.08 ) $ (0.13 ) Year Ended December 31, 2019 First Second Third Fourth Revenue $ 5,407 $ 85 $ 454 $ 3,916 Operating expenses $ 5,855 $ 5,082 $ 5,168 $ 9,542 Net loss $ (1,339 ) $ (5,637 ) $ (5,260 ) $ (6,409 ) Net loss per share – basic and diluted $ (0.18 ) $ (0.39 ) $ (0.32 ) $ (0.13 )

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	Sep. 15, 2021	Oct. 13, 2020	Jul. 13, 2020	Mar. 02, 2020	Sep. 30, 2019	Apr. 11, 2019	Mar. 20, 2019	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2021	Dec. 03, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Jun. 08, 2020	Jun. 07, 2020
Stock Issued During Period, Shares, New Issues (in shares)							1,200,000
Gross Proceeds from Issuance of Common Stock							$ 3,000,000
Proceeds from Issuance of Common Stock							2,500,000			$ 0	$ 9,175,000	$ 2,540,000
Payments of Stock Issuance Costs							$ 320,000
Proceeds from Warrant Exercises										1,849,000	25,951,000	180,000
Payments for Aggregate Commissions to Underwriters						$ 750,000
Proceeds From Exercise of Pre-funded Warrants										$ 0	$ 0	1,226,000
Common Stock, Par or Stated Value Per Share (in dollars per share)									$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.10
Common Stock, Shares Authorized (in shares)									150,000,000	150,000,000	150,000,000		150,000,000	150,000,000		150,000,000	150,000,000	150,000,000	150,000,000	100,000,000
Stock Issued During Period, Value, New Issues												2,440,000
The April 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues, Excluding Shares Sold to Underwriters (in shares)						925,455
Shares Issued, Price Per Share (in dollars per share)						$ 1.10
Proceeds from Issuance or Sale of Equity, Total						$ 9,300,000
Proceeds from Issuance or Sale of Equity, Net						$ 8,100,000
The September 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues, Excluding Shares Sold to Underwriters (in shares)					26,124,828
Shares Issued, Price Per Share (in dollars per share)					$ 0.30
Pre-funded Warrant Price (in dollars per share)					0.20
Pre-funded Warrant, Accompanying Warrant, Amount Paid Per Share (in dollars per share)					$ 0.10
Payments for Aggregate Commissions to Underwriters					$ 713,000
Proceeds from Issuance or Sale of Equity, Total					8,700,000
Proceeds from Issuance or Sale of Equity, Net					$ 7,700,000
The March 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				4,000,000
Payments of Stock Issuance Costs				$ 775,000
Proceeds from Issuance or Sale of Equity, Total				10,000,000
Proceeds from Issuance or Sale of Equity, Net				$ 9,200,000
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)			12,503,806
Proceeds from Issuance of Common Stock			$ 97,000,000							$ 122,210,000	$ 101,934,000	$ 0
Stock Issued During Period, Value, New Issues			$ 100,000,000
Open Market Sale Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)									692,651
Proceeds from Issuance of Common Stock									$ 4,900,000
Payments of Stock Issuance Costs		$ 300,000
Stock Issued During Period, Value, New Issues									$ 5,500,000
Open Market Sale Agreement, Maximum Aggregate Offering Price		$ 250,000,000
Open Market Sale Agreement, Sales Commission, Percentage		4.50%
The October 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)										13,239,839			13,932,490
Proceeds from Issuance of Common Stock										$ 127,900,000			$ 133,400,000
Proceeds from Issuance of Common Stock, Net										$ 122,200,000			$ 127,100,000
The September 2021 ATM [Member]
Stock Issued During Period, Shares, New Issues (in shares)								0
Payments of Stock Issuance Costs	$ 200,000
Open Market Sale Agreement, Maximum Aggregate Offering Price	$ 100,000,000
Open Market Sale Agreement, Sales Commission, Percentage	3.00%
Warrants in Connection with March 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							84,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 3.125
Warrants and Rights Outstanding, Term (Year)							5 years
Warrants and Rights Outstanding							$ 100,000
Common Stock Warrants [Member]
Proceeds from Warrant Exercises																	$ 200,000
Class of Warrant or Right, Exercised During Period (in shares)																	67,825	10,410,398
Proceeds from Exercise of Common Stock Warrants																		$ 11,500,000
Warrants in Connection With the April 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						10,454,546
Warrants and Rights Outstanding						$ 333,000
Class of Warrant Right, Number of Pre-funded Warrants Issued During Period (in shares)						8,165,455
Pre-funded Warrant Price (in dollars per share)						$ 1
Pre-funded Warrant, Accompanying Warrant, Amount Paid Per Share (in dollars per share)						$ 0.10
Warrants in Connection With the April 2019 Offering [Member] | Over-Allotment Option [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						1,363,636
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.10	$ 0.10
Class of Warrant or Right, Exercised During Period (in shares)																4,100,000		8,165,455
Class of Warrant Right, Number of Pre-funded Warrants Issued During Period (in shares)					4,100,000
Proceeds From Exercise of Pre-funded Warrants																$ 400,000		$ 800,000
Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.30	$ 1.10
Warrants and Rights Outstanding, Term (Year)					5 years	5 years
Class of Warrant or Right, Exercised During Period (in shares)																30,661,667
Proceeds from Exercise of Common Stock Warrants															$ 9,200,000
Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 1.375
Class of Warrant or Right, Exercised During Period (in shares)																		609,849
Class of Warrant or Right, Issued During Period (in shares)						636,364
Class of Warrant or Right, Period to Expiration (Year)						5 years
Class of Warrant or Right, Issued During Period, Fair Value						$ 333,000
Proceeds from Exercise of Common Stock Warrants																		$ 800,000
Warrants in Connection with the September 2019 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					30,666,667
Warrants and Rights Outstanding					$ 497,000
Warrants in Connection with the September 2019 Offering [Member] | Over-Allotment Option [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					4,000,000
Underwriter Warrants, September 2019 [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.375
Warrants and Rights Outstanding					$ 497,000
Class of Warrant or Right, Exercised During Period (in shares)																2,115,738
Class of Warrant or Right, Issued During Period (in shares)					2,115,738
Class of Warrant or Right, Period to Expiration (Year)					5 years
Proceeds from Exercise of Common Stock Warrants																$ 800,000
The March 2020 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2.50
Warrants and Rights Outstanding, Term (Year)				5 years
Warrants and Rights Outstanding				$ 453,000
Class of Warrant or Right, Exercised During Period (in shares)														1,970,850
Proceeds from Exercise of Common Stock Warrants														$ 4,900,000
The March 2020 Offering Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.125
Warrants and Rights Outstanding				$ 453,000
Class of Warrant or Right, Exercised During Period (in shares)														179,468
Class of Warrant or Right, Issued During Period (in shares)				280,000
Proceeds from Exercise of Common Stock Warrants														$ 600,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 0	$ 0
Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year 3 months 18 days
Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	11 years 9 months
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2021
Laboratory Equipment [Member]
Laboratory equipment (in years) (Year)	5 years
Office Equipment [Member]
Laboratory equipment (in years) (Year)	3 years
Leasehold Improvements [Member]
Leasehold improvements	Shorter of remaining lease term or estimated useful life

Note 3 - Business Combination_2

Note 3 - Business Combination (Details Textual)	Nov. 30, 2021USD ($)
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed	$ 82,000
Prepaid Rent	671,000
Acquisition of Kindred BioSciences [Member]
Business Combination, Consideration Transferred, Total	$ 4,829,000

Note 3 - Business Combination -

Note 3 - Business Combination - Allocation of the Purchase Price to the Fair Value of the Respective Assets and Liabilities Acquired (Details) - USD ($) $ in Thousands	Nov. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Business combination, goodwill acquired		$ 4,508	$ 0
Acquisition of Kindred BioSciences [Member]
Business combination, property and equipment acquired	$ 321
Business combination, goodwill acquired	4,508
Business Combination, Consideration Transferred, Total	$ 4,829

Note 4 - Fair Value of Financ_3

Note 4 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Recurring [Member]
Financial Liabilities Fair Value Disclosure, Total	$ 0	$ 0	$ 0

Note 4 - Fair Value of Financ_4

Note 4 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Money Market Funds [Member]
Money market funds, Fair Value	$ 70,978	$ 60,005
Fair Value, Recurring [Member]
Total assets	109,930
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	24,997
Fair Value, Recurring [Member] | Short-term Investments [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	7,491
Fair Value, Recurring [Member] | Long-term Investments [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	6,464
Fair Value, Recurring [Member] | Money Market Funds [Member]
Money market funds, Fair Value	70,978	60,005
Total assets		60,005
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total assets	70,978
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Short-term Investments [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Short-term Investments [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Long-term Investments [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	70,978	60,005
Total assets		60,005
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total assets	38,952
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Short-term Investments [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	24,997
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Short-term Investments [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	7,491
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Long-term Investments [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	6,464
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	0	0
Total assets		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total assets	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Short-term Investments [Member] | US Treasury Securities [Member]
Investments, Fair Value Disclosure	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Short-term Investments [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Investments, Fair Value Disclosure	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Long-term Investments [Member] | Corporate Debt Securities [Member]
Investments, Fair Value Disclosure	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Money market funds, Fair Value	$ 0	0
Total assets		$ 0

Note 5 - Balance Sheet Compon_3

Note 5 - Balance Sheet Components (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 71,000	$ 334,000
Depreciation, Total	732,000	114,000	$ 504,000
Amortization of Intangible Assets, Total	1,700,000	1,700,000	2,300,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 3,005,000	0	0
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Remaining Life (Year)	7 years 10 months 24 days
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 3,000,000
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Finite-Lived Intangible Asset, Remaining Life (Year)	6 years
Minimum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year 3 months 18 days
Maximum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	11 years 9 months
Restructuring Charges [Member]
Impairment of Right-of-use Asset			120,000
Restructuring Charges [Member] | CALIFORNIA
Asset Impairment Charges, Total			$ 1,152,000
Royalty [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 71,000	$ 334,000

Note 5 - Balance Sheet Compon_4

Note 5 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash and cash equivalents	$ 143,745	$ 126,870	$ 13,526	$ 11,506
Gross Unrealized Loss	(74)	0
Short-term investments	22,742	0
Long-term investments	16,210	0
Investments and Cash	182,771	126,870
Investments and Cash, Fair Value Disclosure	182,697	126,870
US Treasury Securities [Member]
Amortized Cost	25,055
Gross Unrealized Loss	(58)
Estimated Fair Value	24,997
Short-term investments	12,022
Long-term investments	12,975
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Amortized Cost	7,491
Estimated Fair Value	7,491
Short-term investments	7,491
Corporate Debt Securities [Member]
Amortized Cost	6,480
Gross Unrealized Loss	(16)
Estimated Fair Value	6,464
Short-term investments	3,229
Long-term investments	3,235
Cash [Member]
Cash and Cash Equivalents, at Carrying Value	72,767	66,865
Money market funds, Fair Value	72,767	66,865
Cash and cash equivalents	72,767	66,865
Money Market Funds [Member]
Cash and Cash Equivalents, at Carrying Value	70,978	60,005
Money market funds, Fair Value	70,978	60,005
Cash and cash equivalents	$ 70,978	$ 60,005

Note 5 - Balance Sheet Compon_5

Note 5 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, gross	$ 7,906	$ 2,053
Less: accumulated depreciation	(1,305)	(573)
Property and equipment, net	6,601	1,480
Laboratory Equipment [Member]
Property and equipment, gross	5,057	1,759
Office Equipment [Member]
Property and equipment, gross	481	294
Leasehold Improvements [Member]
Property and equipment, gross	1,063	0
Construction in Progress [Member]
Property and equipment, gross	$ 1,305	$ 0

Note 5 - Balance Sheet Compon_6

Note 5 - Balance Sheet Components - Right-of-use Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Right-of-use assets, net	$ 13,168	$ 6,838
Facilities [Member]
Right-of-use assets, net	13,168	6,836
Office Equipment [Member]
Right-of-use assets, net	$ 0	$ 2

Note 5 - Balance Sheet Compon_7

Note 5 - Balance Sheet Components - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Intangible assets, gross	$ 10,680	$ 20,380
Less: accumulated amortization	(56)	(5,019)
Intangible assets, net	10,624	15,361
Developed Technology Rights [Member]
Intangible assets, gross	10,600	20,300
Intellectual Property [Member]
Intangible assets, gross	$ 80	$ 80

Note 5 - Balance Sheet Compon_8

Note 5 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2021USD ($)
2022	$ 1,350
2023	1,350
2024	1,350
2025	1,350
2026	1,350
Thereafter	3,874
Total	$ 10,624

Note 5 - Balance Sheet Compon_9

Note 5 - Balance Sheet Components - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued compensation	$ 2,786	$ 1,618
Accrued clinical and manufacturing expenses	986	1,772
Accrued professional and consulting services	556	777
Other liabilities, current portion	736	632
Total	$ 5,064	$ 4,799

Note 6 - Revenue (Details Textu

Note 6 - Revenue (Details Textual) - USD ($)	Jun. 28, 2018	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2015
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total		$ 0				$ 0								$ 0	$ 0
Contract With Customer, Asset, Revenue Recognized		0				219,000								0	219,000
Contract with Customer, Liability, Total		0				0								0	0
Revenue, Remaining Performance Obligation, Amount		0				13,000								0	13,000
Revenue from Contract with Customer, Including Assessed Tax		$ 74,000	$ 200,000	$ 112,000	$ 506,000	$ 356,000	$ 265,000	$ 523,000	$ 2,902,000	$ 3,916,000	$ 454,000	$ 85,000	$ 5,407,000	892,000	4,046,000	$ 9,862,000
Income Tax Expense (Benefit), Total														$ 107,000	238,000	490,000
Foreign Tax Authority [Member] | National Tax Agency, Japan [Member]
Royalty Withholding Tax														5.00%
Income Tax Expense (Benefit), Total														$ 44,000	183,000	435,000
Government Contract [Member]
Contract Value	$ 15,700,000																$ 14,000,000
Contract Value, Adjustment	$ 1,700,000
Contract with Customer, Asset, Credit Loss Expense (Reversal)														20,000
Contract with Customer, Asset, Allowance for Credit Loss, Writeoff																20,000
Revenue from Contract with Customer, Including Assessed Tax														0	0	(20,000)
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax														0	2,962,000	4,446,000
Royalty [Member] | GSK Research and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax														0	193,000	778,000
Royalty [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax														$ 0	2,769,000	3,668,000
Royalty Percentage														4.00%
Non Cash Royalty Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax														$ 879,000	886,000	5,030,000
Non Cash Royalty Revenue [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax														$ 879,000	$ 886,000	$ 5,030,000

Note 7 - Liabilities Related _3

Note 7 - Liabilities Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2016	Dec. 31, 2021
Re-valuation Gain Recognized		$ 3.8
HCRP [Member]
Proceeds from Sale of Future Royalties, Net	$ 20
Royalty Interest Due Each Year	$ 3
Royalty Interest, Percentage of Additional Royalties Due Each Year	15.00%
Royalty Interest, Additional Royalties Due Each Year	$ 1

Note 7 - Liabilities Related _4

Note 7 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revaluation gain recognized	$ (3,800)
Current portion	(836)	$ (2,779)
Long-term portion	10,686	$ 12,150
HealthCare Royalty Partners III, L.P. [Member] | Royalty Arrangement [Member]
Total liability related to sale of future royalties, start of year	14,929
Non-cash royalty revenue paid to HCRP	(1,098)
Non-cash interest expense recognized	1,480
Revaluation gain recognized	(3,789)
Total liability related to sale of future royalties, end of year	11,522
Current portion	(836)
Long-term portion	$ 10,686

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2021	Jul. 31, 2019
Operating Lease, Weighted Average Discount Rate, Percent	9.27%
Operating Lease, Weighted Average Remaining Lease Term (Year)	6 years 11 months 4 days
Lessee, Finance Lease, Number of Leases				0
Operating Lease, Payments	$ 4,400,000	$ 1,100,000	$ 983,000
Right of Use for Office and Manufacturing Facilities with Initial Terms Exceeding One Year [Member]
Lessee, Operating Lease, Number of Right-of-Use Leases	5
Right of Use for Equipment with Initial Terms Exceeding One Year [Member]
Lessee, Operating Lease, Number of Right-of-Use Leases	1
Leases for Manufacturing Facilities with Initial Terms of One Year or Less [Member]
Lessee, Short-term Lease, Number of Leases	3
Lease Agreements for Manufacturing Equipment with Initial Terms of One Year or Less [Member]
Lessee, Short-term Lease, Number of Leases	1
South San Francisco Real Estate [Member]
Lessee, Operating Lease, Renewal Term (Year)	8 years				5 years
Facility in South San Francisco [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years
Facility in Burlingame, California [Member]
Lessee, Operating Lease, Renewal Term (Year)	30 months
Lessee, Operating Lease, Number of Renewal Option	2
Gain (Loss) on Termination of Lease	$ 116,000
Facilities Under Operating Leases [Member]
Short-term Lease Commitment, Amount	14,000
Equipment Under Operating Leases [Member]
Short-term Lease Commitment, Amount	$ 8,000

Note 8 - Leases - Lease Liabili

Note 8 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
2022	$ 2,071
2023	2,123
2024	2,195
2025	2,297
2026	2,852
Thereafter	6,770
Undiscounted total	18,308
Less: imputed interest	(5,300)
Present value of future minimum payments	13,008
Current portion of operating lease liability	(1,011)	$ (2,052)
Operating lease liability, net of current portion	$ 11,997	$ 5,156

Note 8 - Leases - Operating Lea

Note 8 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating lease cost	$ 2,513	$ 1,145	$ 959
Short-term lease cost	340	13	15
Variable lease cost	1,233	264	162
Sublease income	(36)	(217)	(217)
Total lease cost	$ 4,050	$ 1,205	$ 919

Note 9 - Secured Promissory N_2

Note 9 - Secured Promissory Note Payable to Oxford Finance (Details Textual) - USD ($)	Nov. 04, 2019	Dec. 22, 2016	Dec. 31, 2019	Feb. 13, 2018
Amortization of Debt Issuance Costs	$ 98,000
Legal Fees	$ 2,000
Warrants in Connection with Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		7,563		10,914
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 33.11		$ 22.99
Warrants Not Settleable in Cash, Fair Value Disclosure		$ 134,000
Loan Agreement [Member] | Oxford Finance [Member]
Long-term Debt, Gross		$ 5,000,000
Debt Instrument, Term (Year)		4 years
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid		$ 325,000
Debt Instrument, Interest Rate, Effective Percentage				10.50%
Interest Expense, Debt, Total			$ 311,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total			$ 223,000
Loan Agreement [Member] | Oxford Finance [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		6.17%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Purchase Obligation, Total	$ 11
Long-term Purchase Commitment, Period (Month)	18 months
Lessee, Operating Lease, Lease Not yet Commenced	$ 14.9

Note 11 - Stockholders' Equit_2

Note 11 - Stockholders' Equity (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 02, 2020	Sep. 30, 2019	Apr. 11, 2019	Mar. 20, 2019
Preferred Stock, Shares Authorized (in shares)	5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0	0
Dividends, Total	$ 0
Warrants in Connection with March 2019 Offering [Member]
Warrants and Rights Outstanding						$ 100,000
The March 2020 Offering Placement Agent Warrants [Member]
Warrants and Rights Outstanding			$ 453,000
Warrants in Connection With the April 2019 Offering [Member]
Warrants and Rights Outstanding					$ 333,000
Underwriter Warrants, September 2019 [Member]
Warrants and Rights Outstanding				$ 497,000
First Set of Warrants Expiring September 2024 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	$ 0.30
First Set of Warrants Expiring April 2024 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	1.10
Warrants Expiring March 2025 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	2.50
Warrants Expiring February 2025 [Member]
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)	$ 3.125

Note 11 - Stockholders' Equit_3

Note 11 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Dec. 31, 2021	Dec. 31, 2020
Common stock reserved for issuance (in shares)	16,031,282	9,288,870
Options Issued and Outstanding [Member]
Common stock reserved for issuance (in shares)	10,216,106	6,813,033
Options Available for Future Grants [Member]
Common stock reserved for issuance (in shares)	5,582,742	1,230,863
Common Warrants [Member]
Common stock reserved for issuance (in shares)	232,434	1,244,974

Note 11 - Stockholders' Equit_4

Note 11 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Dec. 31, 2021$ / sharesshares
Warrants outstanding (in shares)	232,434
First Set of Warrants Expiring September 2024 [Member]
Warrants outstanding (in shares)	5,000
Exercise Price (in dollars per share) | $ / shares	$ 0.30
First Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	44,148
Exercise Price (in dollars per share) | $ / shares	$ 1.10
Second Set of Warrants Expiring April 2024 [Member]
Warrants outstanding (in shares)	26,515
Exercise Price (in dollars per share) | $ / shares	$ 1.375
Warrants Expiring March 2025 [Member]
Warrants outstanding (in shares)	29,150
Exercise Price (in dollars per share) | $ / shares	$ 2.50
Warrants Expiring February 2025 [Member]
Warrants outstanding (in shares)	100,532
Exercise Price (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring March 2024 [Member]
Warrants outstanding (in shares)	16,175
Exercise Price (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring December 2026 [Member]
Warrants outstanding (in shares)	10,914
Exercise Price (in dollars per share) | $ / shares	$ 22.99

Note 11 - Stockholders' Equit_5

Note 11 - Stockholders' Equity - Assumptions for Fair Value of Warrants (Details)	Mar. 02, 2020USD ($)shares	Sep. 30, 2019USD ($)shares	Apr. 11, 2019USD ($)shares	Mar. 20, 2019USD ($)shares
Warrants in Connection with March 2019 Offering [Member]
Aggregate valuation on issuance date | $				$ 100,000
Number of warrants issued (in shares) | shares				84,000
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				3.125
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Share Price [Member]
Measurement Input				2.08
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0234
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.80
Warrants in Connection with March 2019 Offering [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0
Warrants in Connection With the April 2019 Offering [Member]
Aggregate valuation on issuance date | $			$ 333,000
Number of warrants issued (in shares) | shares			636,364
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			1.375
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.89
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0231
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Expected Term [Member]
Measurement Input			5
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.83
Warrants in Connection With the April 2019 Offering [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Warrants in Connection with the September 2019 Offering [Member]
Aggregate valuation on issuance date | $		$ 497,000
Number of warrants issued (in shares) | shares		2,115,738
Warrants in Connection with the September 2019 Offering [Member] | Measurement Input, Exercise Price [Member]
Measurement Input		0.375
Warrants in Connection with the September 2019 Offering [Member] | Measurement Input, Share Price [Member]
Measurement Input		0.36
Warrants in Connection with the September 2019 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0155
Warrants in Connection with the September 2019 Offering [Member] | Measurement Input, Expected Term [Member]
Measurement Input		5
Warrants in Connection with the September 2019 Offering [Member] | Measurement Input, Price Volatility [Member]
Measurement Input		0.83
Warrants in Connection with the September 2019 Offering [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Warrants in Connection with March 2020 Offering [Member]
Aggregate valuation on issuance date | $	$ 453,000
Number of warrants issued (in shares) | shares	280,000
Warrants in Connection with March 2020 Offering [Member] | Measurement Input, Exercise Price [Member]
Measurement Input	3.125
Warrants in Connection with March 2020 Offering [Member] | Measurement Input, Share Price [Member]
Measurement Input	2.34
Warrants in Connection with March 2020 Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input	0.0088
Warrants in Connection with March 2020 Offering [Member] | Measurement Input, Expected Term [Member]
Measurement Input	4.99
Warrants in Connection with March 2020 Offering [Member] | Measurement Input, Price Volatility [Member]
Measurement Input	0.98
Warrants in Connection with March 2020 Offering [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input	0

Note 12 - Equity Incentive Pl_3

Note 12 - Equity Incentive Plans (Details Textual) - USD ($)	Jun. 16, 2021	Jun. 15, 2021	Jul. 24, 2020	Jul. 20, 2020	Jul. 09, 2020	Jun. 15, 2020	Apr. 23, 2019	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 08, 2020	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)									10,216,106	6,813,033	1,811,652		865,163
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)									$ 4.96	$ 2.70	$ 2.74		$ 8.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)									8 years 8 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value									$ 18,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)									9,577,757
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)									$ 4.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)									8 years 7 months 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value									$ 18,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)									3,743,237
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)									$ 2.71
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)									7 years 7 months 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value									$ 14,200,000
Share Price (in dollars per share)									$ 6.27
Proceeds from Stock Options Exercised									$ 1,745,000	$ 602,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)									1,070,921	414,676	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value									$ 6,200,000	$ 2,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)									5,178,438	5,579,800	1,791,030
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)									$ 7.09	$ 2.66	$ 0.67
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate									0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)									$ 6.49	$ 2.49	$ 0.48
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount									$ 28,600,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)									3 years 25 days
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate									131.00%	111.00%	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate									1.35%	0.88%	2.31%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)									6 years 29 days	10 years	10 years
Chief Executive Officer [Member] | Performance-based Options [Member]
Share Price (in dollars per share)						$ 2.46
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						900,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate						105.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						0.35%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)						5 years 2 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value						$ 279,000
Chief Executive Officer [Member] | Performance-based Options [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)					$ 5	$ 5
Chief Executive Officer [Member] | Performance-based Options [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)				$ 7.50		$ 7.50
Chief Executive Officer [Member] | Performance-based Options [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Minimum Closing Price for Ten Consecutive Trading Days (in dollars per share)			$ 10			$ 10
Chief Executive Officer [Member] | Performance-based Options and Time-based Options [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)						$ 2.46
Former Chairman of the Board [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		3 months
Former Chairman of the Board [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Jun. 16, 2023
Former Chairman of the Board [Member] | Stock Options with Accelerated Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number (in shares)	100,000
Share-based Payment Arrangement, Plan Modification, Incremental Cost								$ 1,300,000
The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	16,900,000						1,600,000					8,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)							10 years

Note 12 - Equity Incentive Pl_4

Note 12 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Shares available for grant, balance (in shares)	1,230,863	295,180	200,650
Number of options outstanding, beginning balance (in shares)	6,813,033	1,811,652	865,163
Weighted average exercise price, balance (in dollars per share)	$ 2.70	$ 2.74	$ 8.13
Shares availabe for grant, 2019 Plan Amendment (in shares)	8,900,000	6,400,000	1,600,000
Shares available for grant, removed from 2016 Plan (in shares)			(223,389)
Shares available for grant, granted (in shares)	(5,178,438)	(5,579,800)	(1,791,030)
Number of options outstanding, granted (in shares)	5,178,438	5,579,800	1,791,030
Weighted average exercise price, granted (in dollars per share)	$ 7.09	$ 2.66	$ 0.67
Shares available for grant, forfeited (in shares)	630,317	105,910	483,849
Number of options outstanding, forfeited (in shares)	(650,054)	(105,992)	(592,528)
Weighted average exercise price, forfeited (in dollars per share)	$ 3.16	$ 1.65	$ 1.57
Shares available for grant, canceled (in shares)	0	9,573	25,100
Number of options outstanding, canceled (in shares)	(54,390)	(57,751)	(252,013)
Weighted average exercise price, canceled (in dollars per share)	$ 11.98	$ 10.57	$ 9.25
Number of options outstanding, exercised (in shares)	(1,070,921)	(414,676)	0
Weighted average exercise price, exercised (in dollars per share)	$ 1.63	$ 1.45
Shares available for grant, balance (in shares)	5,582,742	1,230,863	295,180
Number of options outstanding, balance (in shares)	10,216,106	6,813,033	1,811,652
Weighted average exercise price, balance (in dollars per share)	$ 4.96	$ 2.70	$ 2.74

Note 12 - Equity Incentive Pl_5

Note 12 - Equity Incentive Plans - Assumptions of Options (Details) - Share-based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Risk-free interest rate	0.91%	0.40%	1.68%
Expected term (in years) (Year)	5 years 5 months 8 days	5 years 2 months 19 days	5 years 4 months 20 days
Expected volatility	122.00%	94.00%	83.00%
Maximum [Member]
Risk-free interest rate	1.35%	0.88%	2.31%
Expected term (in years) (Year)	6 years 29 days	10 years	10 years
Expected volatility	131.00%	111.00%	85.00%

Note 12 - Equity Incentive Pl_6

Note 12 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - Share-based Payment Arrangement, Option [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation	$ 8,867	$ 4,358	$ 627
Research and Development Expense [Member]
Stock-based compensation	4,304	1,563	253
General and Administrative Expense [Member]
Stock-based compensation	$ 4,563	$ 2,795	$ 374

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual)	1 Months Ended
	Apr. 30, 2020USD ($)
Disgorgement of Stockholder Short-swing Profits [Member]
Related Party Transaction, Amounts of Transaction	$ 652,000

Note 14 - Restructuring Charg_3

Note 14 - Restructuring Charges (Reversals) (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Payments for Restructuring			$ 2,799,000	$ 1,272,000
Restructuring Charges (Reversals)		$ 0	(849,000)	4,920,000
Restructuring Reserve, Ending Balance		$ 0	0	3,648,000	$ 0
Contract Termination [Member]
Payments for Restructuring	$ 2,252,000		2,252,000	0
Restructuring Reserve, Ending Balance			$ 0	$ 3,223,000	$ 0

Note 14 - Restructuring Charg_4

Note 14 - Restructuring Charges (Reversals) - Restructuring Liabilities (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021
Cumulative cost incurred				$ 4,071,000
Balance		$ 3,648,000	$ 0
Period charges		122,000	4,920,000
Settlements		(2,799,000)	(1,272,000)
Period reversals		(971,000)
Balance		0	3,648,000
Contract Termination [Member]
Cumulative cost incurred				2,252,000
Balance		3,223,000	0
Period charges		0	3,223,000
Settlements	$ (2,252,000)	(2,252,000)	0
Period reversals		(971,000)
Balance		0	3,223,000
Employee Severance [Member]
Cumulative cost incurred				368,000
Balance		368,000	0
Period charges		0	368,000
Settlements		(368,000)	0
Period reversals		0
Balance		0	368,000
Impairment Charges [Member]
Cumulative cost incurred				1,272,000
Balance		0	0
Period charges		0	1,272,000
Settlements		0	(1,272,000)
Period reversals		0
Balance		0	0
Other Restructuring [Member]
Cumulative cost incurred				$ 179,000
Balance		57,000	0
Period charges		122,000	57,000
Settlements		(179,000)	0
Period reversals		0
Balance		$ 0	$ 57,000

Note 15 - Benefit Plan (Details

Note 15 - Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%
Defined Contribution Plan, Cost	$ 288,000	$ 96,000	$ 140,000
Defined Contribution Plan, Administrative Expense	$ 14,000	$ 10,000	$ 14,000

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	21.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 20,600	$ 8,600	$ (35,300)
Unrecognized Tax Benefits, Ending Balance	2,422	1,281	851	$ 1,582
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total	0	0	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	115,900	51,600	18,000
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	3,100	900	100
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	$ 84,800	26,800	1,600
Open Tax Year	2016 2017 2018 2019 2020 2021
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 5,000	$ 3,400	$ 2,700
Foreign Tax Authority [Member] | Australian Taxation Office [Member]
Operating Loss Carryforwards, Total	$ 6,700

Note 16 - Income Taxes - Compon

Note 16 - Income Taxes - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 0	$ 0	$ 0
State	1	3	2
Foreign	106	235	488
Total Current	107	238	490
Deferred:
Federal	0	0	0
State	0	0	0
Foreign	0	0	0
Total Deferred	0	0	0
Provision for income taxes	$ 107	$ 238	$ 490

Note 16 - Income Taxes - Comp_2

Note 16 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforwards	$ 30,256	$ 14,161	$ 6,924
Research and development tax credits	4,923	2,497	1,591
Capitalized research and development	4,016	4,534	4,773
Sale of future royalties	5,826	7,178	7,486
Lease liability	3,184	1,695	492
Accruals, reserves and other	3,043	1,327	1,253
Total deferred tax assets	51,248	31,392	22,519
Valuation allowance	(42,589)	(21,952)	(13,365)
Deferred tax assets net of valuation allowance	8,659	9,440	9,154
Intangible assets	(5,410)	(7,832)	(8,730)
Right-of-use assets	(3,223)	(1,608)	(424)
Depreciation on property and equipment	(26)	0	0
Total deferred tax liabilities	(8,659)	(9,440)	(9,154)
Net deferred tax assets	$ 0	$ 0	$ 0

Note 16 - Income Taxes - Reconc

Note 16 - Income Taxes - Reconciliation of Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
U.S. federal taxes at statutory rate	21.00%	21.00%	21.00%
State taxes (net of federal benefit)	4.00%	2.90%	0.40%
Foreign rate differential	0.30%	(0.70%)	(2.60%)
Permanently non-deductible items	0.20%	2.20%	(3.70%)
Tax credits	3.40%	2.80%	1.70%
Change in valuation allowance	(29.30%)	(26.80%)	194.20%
Tax attributes write-off due to change in control	0.00%	0.50%	(208.30%)
Prior year true-up	0.60%	(2.50%)	(0.90%)
Other	(0.30%)	(0.10%)	(4.50%)
Provision for income taxes	(0.10%)	(0.70%)	(2.70%)

Note 16 - Income Taxes - Unreco

Note 16 - Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Beginning Balance	$ 1,281	$ 851	$ 1,582
Additions based on tax positions related to the current year	1,132	431	159
Increase related to prior years’ tax positions	9
Decrease related to prior years’ tax positions		(1)	(890)
Ending Balance	$ 2,422	$ 1,281	$ 851

Note 17 - Net Loss Per Share _3

Note 17 - Net Loss Per Share Attributable to Common Stockholders (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Dilutive Securities, Effect on Basic Earnings Per Share, Total	$ 0	$ 0	$ 0

Note 17 - Net Loss Per Share _4

Note 17 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (20,764)	$ (17,583)	$ (16,116)	$ (16,007)	$ (13,861)	$ (8,085)	$ (8,977)	$ (1,297)	$ (6,409)	$ (5,260)	$ (5,637)	$ (1,339)	$ (70,470)	$ (32,220)	$ (18,645)
Shares used to compute net loss per share – basic and diluted (in shares)													121,453,723	88,295,762	21,569,523
Net loss per share – basic and diluted (in dollars per share)	$ (0.17)	$ (0.14)	$ (0.13)	$ (0.14)	$ (0.13)	$ (0.08)	$ (0.12)	$ (0.02)	$ (0.13)	$ (0.32)	$ (0.39)	$ (0.18)	$ (0.58)	$ (0.36)	$ (0.86)

Note 17 - Net Loss Per Share _5

Note 17 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	8,575,180	19,183,231	19,163,520
Share-based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	8,206,137	4,409,806	1,583,575
Warrant [Member] | Common Stock [Member]
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	369,043	14,773,425	17,579,945

Note 18 - Quarterly Financial_3

Note 18 - Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue	$ 74	$ 200	$ 112	$ 506	$ 356	$ 265	$ 523	$ 2,902	$ 3,916	$ 454	$ 85	$ 5,407	$ 892	$ 4,046	$ 9,862
Operating expenses	24,289	17,451	15,887	16,017	13,717	7,854	9,049	3,596	9,542	5,168	5,082	5,855	73,644	34,216	25,647
Net loss	$ (20,764)	$ (17,583)	$ (16,116)	$ (16,007)	$ (13,861)	$ (8,085)	$ (8,977)	$ (1,297)	$ (6,409)	$ (5,260)	$ (5,637)	$ (1,339)	$ (70,470)	$ (32,220)	$ (18,645)
Net loss per share – basic and diluted (in dollars per share)	$ (0.17)	$ (0.14)	$ (0.13)	$ (0.14)	$ (0.13)	$ (0.08)	$ (0.12)	$ (0.02)	$ (0.13)	$ (0.32)	$ (0.39)	$ (0.18)	$ (0.58)	$ (0.36)	$ (0.86)

Note 19 - Subsequent Events (De

Note 19 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	Mar. 20, 2019	Sep. 30, 2021	Feb. 24, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock Issued During Period, Shares, New Issues (in shares)	1,200,000
Proceeds from Issuance of Common Stock	$ 2,500			$ 0	$ 9,175	$ 2,540
The September 2021 ATM [Member]
Stock Issued During Period, Shares, New Issues (in shares)		0
The September 2021 ATM [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)			216,000
Proceeds from Issuance of Common Stock			$ 1,000